Mid Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
Qiagen
QGEN
$9.5B
| $9.5B | $46.13 | 0.09% |
|
2
RadNet
RDNT
$5.41B
| $5.41B | $68.80 | 2.29% |
|
3
GRAIL Inc
GRAL
$5.26B
| $5.26B | $117.81 | 13% |
|
4
Sotera Health
SHC
$5.11B
| $5.11B | $17.89 | 1% |
|
5
BillionToOne Inc
BLLN
$4.63B
| $4.63B | $98.12 | 4.49% |
|
6
Adaptive Biotechnologies
ADPT
$3.83B
| $3.83B | $24.02 | 6.1% |
|
7
Veracyte
VCYT
$3.47B
| $3.47B | $43.12 | 2.86% |
|
8
CareDx
CDNA
$3.31B
| $3.31B | $64 | 4.02% |
|
9
NeoGenomics
NEO
$2.14B
| $2.14B | $16.65 | 3.48% |
|
Mid Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 9 mid cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap between $2B and $10B — worth a combined $42.7B.
The largest by market cap are Qiagen (QGEN) at $9.5B, RadNet (RDNT) at $5.41B and GRAIL Inc (GRAL) at $5.26B.
Among institutional investors, BillionToOne Inc (BLLN) drew the most net new fund positions in Q2 2026: 76 funds opened new positions, taking total fund holders up 65 (71%) quarter-over-quarter.
- Combined market cap: $42.7B across 9 stocks.
- Mid Cap: market cap between $2B and $10B.
- Largest constituent: Qiagen (QGEN), $9.5B market cap.
- Most net new fund positions in Q2 2026: BillionToOne Inc (BLLN), +65 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.